Oragenics Aktie [WKN DE: A0CABC / ISIN: US6840231046]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Oragenics IncShs

19.04.24		Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards (Businesswire)
01.04.24		Oragenics, Inc. Files 10K and Provides Company Update (Businesswire)
18.03.24		Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion (Businesswire)
01.03.24		Oragenics Announces Closing of Public Offering (Businesswire)
28.02.24		Oragenics Announces Pricing of Public Offering (Businesswire)
27.02.24		Oragenics Announces Proposed Public Offering (Businesswire)
12.02.24		Oragenics, Inc. Announces Leadership Transition (Businesswire)
07.02.24		Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement (Businesswire)
05.02.24		Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion (Businesswire)
23.01.24		Oragenics Announces Termination of At-The-Market Offering Program (Businesswire)
02.01.24		Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets (Businesswire)
02.11.23		Oragenics Issues Update to Shareholders (Businesswire)
18.10.23		Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors (Businesswire)
05.10.23		Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate (Businesswire)
29.09.23		Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets (Businesswire)
07.08.23		Oragenics, Inc. Announces Private Placement (Businesswire)
29.03.23		Oragenics to Participate in the World Vaccine Congress Washington (Businesswire)
08.03.23		Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team (Businesswire)
03.02.23		Oragenics, Inc. Regains Compliance with NYSE American (Businesswire)
23.12.22		Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split (Businesswire)
22.12.22		Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate (Businesswire)
20.12.22		Oragenics, Inc. Receives NYSE American Notice (Businesswire)
24.10.22		Oragenics to Participate in the 2022 BioFlorida Annual Conference (Businesswire)
24.08.22		Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate (Businesswire)
23.06.22		Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer (Businesswire)
14.06.22		Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports (Businesswire)
17.05.22		Oragenics Issues Letter to Shareholders (Businesswire)
18.04.22		Oragenics to Participate at the World Vaccine Congress Washington 2022 (Businesswire)
06.04.22		Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses (Businesswire)
25.03.22		Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation (Businesswire)
22.03.22		Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1 (Businesswire)
10.03.22		Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1 (Businesswire)
03.03.22		Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript (Businesswire)
26.01.22		Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum (Businesswire)
20.12.21		Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant (Businesswire)
09.12.21		Oragenics to Participate in Virtual Fireside Chat Hosted by Alliance Global Partners (Businesswire)
08.12.21		Oragenics Co-Authors a Publication Describing the Dual Mechanism of Action of Lantibiotics (Businesswire)
01.12.21		Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate (Businesswire)
01.07.21		Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum (Businesswire)
18.05.21		Oragenics Issues Letter to Shareholders (Businesswire)
03.05.21		Oragenics Announce Changes in Management and Board of Directors (Businesswire)
09.03.21		Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine (Businesswire)
08.03.21		Oragenics to Participate in Two Investment Conferences During March (Businesswire)
02.02.21		SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice (Businesswire)
14.01.21		Oragenics Issues Letter to Stockholders (Businesswire)
29.12.20		Oragenics Announces Closing of $6.5 Million Registered Direct Offering (Businesswire)
06.10.20		FDA Broadly Supports Oragenics’ Pre-IND Development Program for its SARS-CoV-2 Vaccine (Businesswire)
28.09.20		Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine (Businesswire)
11.09.20		Oragenics Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference (Businesswire)
20.08.20		Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Flugzeugabsturz nahe Vilnius: DHL-Auftragnehmer in schweren Unfall verwickelt - DHL-Aktie etwas schwächer

Italiens UniCredit will Banco BPM schlucken - Scheitert jetzt die Commerzbank-Übernahme? - Aktien unter Druck

Pierer Mobility-Aktie zieht zweistellig an: Pierer Industrie AG hat Restrukturierungsverfahren eingeleitet

Bitcoin im Fokus: MicroStrategy sorgt für Spannung mit potenziellen Käufen

Erstes Alarmsignal seit 2008: Droht dem Aktienmarkt eine Krise?

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	27.11.2024 15:41
Kaufwert:	EUR
	Hinzufügen Speichern